Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds



Natural bioactive compounds as therapeutic candida

Posted on: 20 Mar 03


Benign prostatic hypertrophy (BPH) is very common in men aged 50 years and older. Resultant bladder hyperactivity leads to self-enforced changes in life style, increased frequency of falls in the immo
Natural bioactive compounds as therapeutic candidates for benign prostatic hypertrophy

Benign prostatic hypertrophy (BPH) occurs in up to 50% of men aged 51-60 years and more than 80% in men older than 80 years. Many of these individuals suffer problems with urinary flow which can lead to self-enforced changes in life style, increased frequency of falls and other domestic accidents in the immobile and often institutionalization. Lehman Brothers estimated that the worldwide market value for BPH grew by 12% between 1998-2001, and was expected to grow a further 15% between 2001-2005 (forecast to reach US$3.5 billion) along side growing awareness of BPH and population aging.

The BPH market is characterized by a general consumer and clinician acceptance for phytotherapeutics. Indeed BioMerieux-Pierre Fabre's Permixon, an extract of saw palmetto with 5-a-reductase inhibitory activity holds a large share of the market. The BPH therapeutics market has progressed little over the past 10 years with respect to new targets and is likely to remain focused on small molecule 5-a-reductase inhibitors, a-adrenoceptor antagonists as well as phytotherapeutics for the foreseeable future.

Hurdles to the phytotherapeutic sector are largely related to non-stringent extraction processes, quality control and variability in starting materials. Naturamed is a start-up company that has developed a stringent supply and extraction/purification process to produce phytotherapeutics with efficacy against well-established targets for the treatment of BPH. Activity was identified in a number of distinct natural bioactive (termed "NABIA") fractions purified from a single plant. These fractions were able to both antagonize 5-a-reductase and block a-adrenoceptors with an efficacy similar to reference treatments. This dual approach offers an improved approach to BPH as well as additional therapeutic potential for the treatment of erectile dysfunction, a condition that is highly prevalent in the same population segment. Clinical trials are anticipated to commence in 2003 and corporate partners are now being sought to speed the development of NABIA fractions towards the market. Partners are likely to come from the drug development sector. For free access to the full dossier of this project Click here or paste the following address into your browser:

For further information on LeadDiscovery please visit our website at

Other reports of interest:

Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets [click here to access]

HMP-12 an adrenoceptor antagonist for the treatment of male and female sexual dysfunction [click here to access]


Last updated on: 27/08/2010 11:40:18

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.